Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

4.7K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
4.7K
Positron Emission Tomography01:29

Positron Emission Tomography

6.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

[French ccAFU guidelines - update 2020-2022: prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same author

[French ccAFU guidelines - Update 2018-2020: Prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2019
Same author

RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate French ccAFU guidelines – Update 2018–2020: Prostate cancer

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2018
Same author

[CCAFU french national guidelines 2016-2018 on prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2016
Same author

[Prostate cancer imaging: MRI and nuclear imaging].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2015

Related Experiment Video

Updated: May 4, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K

[Focus: Prostate cancer and PET-choline].

I Brenot-Rossi1

  • 1Département de médecine nucléaire, institut Paoli-Calmettes, 232, boulevard de Sainte-Marguerite, 13232 Marseille cedex 9, France.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|December 25, 2013
PubMed
Summary

Positron emission tomography (PET) with (18)F-Fluorocholine is authorized for diagnosing bone metastases in prostate cancer. This imaging technique aids in staging and detecting recurrent disease, offering a comprehensive approach to cancer management.

Keywords:
Cancer de prostateFCHFluorocholineLymph node stagingMetastasisMétastasePETProstate cancerStadification ganglionnaireTEP

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
11:43

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

10.1K

Related Experiment Videos

Last Updated: May 4, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
11:43

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging

Published on: December 30, 2016

10.1K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiology

Background:

  • (18)F-Fluorocholine PET is approved for diagnosing bone metastases.
  • Androgen deprivation therapy should not be altered before the scan.
  • Choline uptake correlates with prostate tumor size (>5 mm) and is useful for negative biopsies.

Purpose of the Study:

  • To evaluate the utility of (18)F-Fluorocholine PET in staging and detecting prostate cancer recurrence.
  • To assess its efficacy in identifying metastatic nodes and bone lesions.
  • To explore its role in guiding salvage treatment decisions.

Main Methods:

  • Utilizing (18)F-Fluorocholine PET for initial staging of high-risk prostate cancer.
  • Employing the scan for detecting metastatic nodes (>5 mm) outside lymphadenectomy areas.
  • Using PET-choline for evaluating recurrent disease, including local, nodal, and bone metastases, with specific PSA thresholds and relapse parameters.

Main Results:

  • PET-choline is highly effective for detecting intra-medullary bone metastases.
  • It can stage nodal (N) and distant metastatic (M) disease in a single procedure.
  • The scan detects relapse sites (local, pelvic nodal, bone) at PSA thresholds of 1 ng/mL, with enhanced sensitivity for rapid PSA velocity or short doubling times.
  • Furosemide can mitigate bladder accumulation, improving visualization of local recurrence.

Conclusions:

  • (18)F-Fluorocholine PET is a valuable tool for staging and detecting prostate cancer, potentially replacing conventional imaging.
  • It is particularly useful for identifying early-stage bone metastases and recurrent disease.
  • The scan aids in treatment decisions, including salvage therapy, especially in cases of rising PSA levels.